Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group

Published:2013-10-24 Issue:1 Volume:10 Page:60-65
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Tafreshi Ali¹,Thientosapol Eddy²,Liew Mun Sem¹,Guo Yuan¹,Quaggiotto Melissa²,Boyer Michael²,Davis Ian D¹³

Affiliation:

1. Joint Austin-Ludwig Oncology Unit; Austin Health; Melbourne Victoria Australia

2. Department of Medical Oncology; Royal Prince Alfred Hospital; Sydney New South Wales Australia

3. Eastern Health Clinical School; Monash University; Melbourne Victoria Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12122/fullpdf

Reference20 articles.

1. International Agency for Research on Cancer The GLOBOCAN project: cancer incidence and mortality worldwide in 2008 2010 http://globocan.iarc.fr/

2. Targeted therapy for advanced renal cell carcinoma;Coppin;Cochrane Database Syst Rev,2008

3. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth;Kondo;PLoS Biol,2003

4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

5. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction;Cell Death Discovery;2024-03-14

2. 5-Methoxytryptophan enhances the sensitivity of sorafenib on the inhibition of proliferation and metastasis for lung cancer cells;BMC Cancer;2024-02-22

3. MCL1 Inhibition: A Promising Approach to Augment the Efficacy of Sorafenib in NSCLC through Ferroptosis Induction;2023-09-25

4. Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study;BMC Cancer;2021-01-05

5. Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells;Oncology Letters;2018-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3